Drivetime Radio Productions

As Australia's longest-running broadcast exclusively for healthcare professionals, we make it easy to stay-up-to-date, with each specialist interview lasting approximately 25 minutes.

Tune in to our medical broadcasters as they moderate discussions with renowned experts and influential thought leaders.

Stream interviews below or access our private podcast.

Search Interviews

 

Epilepsy Miniseries (Part 4a)

Epilepsy & Preparation for Pregnancy
28-Minutes
Show more info
Play preview - to listen to full interviews
or Subscribe

Epilepsy miniseries Part 4a: While women with epilepsy who desire pregnancy must be managed carefully during the pre-conception, and pre-and post-natal periods, epilepsy is not a contraindication for pregnancy. The care of women with epilepsy who desire pregnancy has changed significantly over the last 30 years, with more than 95% of women with epilepsy going on to deliver a healthy child. In this two-part interview, we discuss the management of women with epilepsy who are of childbearing age with 3 experts that have a particular interest in caring for women during the pre-conception and pre-and post-natal periods.

Host

Professor Mark Cook

Consultant Neurologist, Director of Neurology and Chair of Medicine, St Vincent’s Hospital Melbourne.

Guest Experts

  • Dr Kaitlyn Parratt

    Dr Kaitlyn Parratt

    Neurologist, Sharp Neurology, Sydney.

  • Dr Komal Chohan

    Dr Komal Chohan

    Obstetrician and Gynaecologist, Sydney.

  • Susie Hobson

    Susie Hobson

    Midwife and Lactation Consultant, Sydney.


Epilepsy Miniseries (Part 4b)

Epilepsy & Practicalities of Pregnancy
30-Minutes
Show more info
Play preview - to listen to full interviews
or Subscribe

Epilepsy miniseries Part 4b: While women with epilepsy who desire pregnancy must be managed carefully during the pre-conception, and pre-and post-natal periods, epilepsy is not a contraindication for pregnancy. The care of women with epilepsy who desire pregnancy has changed significantly over the last 30 years, with more than 95% of women with epilepsy going on to deliver a healthy child. In this two-part interview, we discuss the management of women with epilepsy who are of childbearing age with 3 experts that have a particular interest in caring for women during the pre-conception and pre-and post-natal periods.

Host

Professor Mark Cook

Consultant Neurologist, Director of Neurology and Chair of Medicine, St Vincent’s Hospital Melbourne.

Guest Experts

  • Dr Kaitlyn Parratt

    Dr Kaitlyn Parratt

    Neurologist, Sharp Neurology, Sydney.

  • Dr Komal Chohan

    Dr Komal Chohan

    Obstetrician and Gynaecologist, Sydney.

  • Susie Hobson

    Susie Hobson

    Midwife and Lactation Consultant, Sydney.


Haematology: ALL Miniseries (Part 2)

The Importance of MRD Testing in ALL
34-Minutes
Show more info
Play preview - to listen to full interviews
or Subscribe

Haematology: Acute Lymphoblastic Leukaemia Miniseries (Part 2): Until now, the use of minimal residual disease (MRD) testing in patients with acute lymphoblastic leukaemia (ALL) outside of a clinical trial program has not been standardised. Testing has been dependent on factors such as patient age and transplant considerations, largely because testing has not been funded through the Medicare Benefits Schedule (MBS). Well, that’s all changed, and now all patients with ALL are eligible for a total of twelve MRD tests per disease episode.

So, how will this affect clinical decisions, what will it mean for the treatment landscape, and how do we decide at what intervals to do these tests? Listen to this two-part interview to learn more…

Host

Associate Professor Ashley Ng

Clinical Haematologist, The Royal Melbourne Hospital & Peter MacCallum Cancer Centre.

Guest Experts

  • Dr Shaun Fleming

    Dr Shaun Fleming

    Consultant Haematologist, Monash Health & Alfred Health, Melbourne.

  • Dr Michael Osborn

    Dr Michael Osborn

    Consultant Haematologist, Royal Adelaide Hospital, Adelaide.


Haematology: ALL Miniseries (Part 1)

Measurable Residual Disease in ALL
30-Minutes
Show more info
Play preview - to listen to full interviews
or Subscribe

Haematology: Acute Lymphoblastic Leukaemia Miniseries (Part 1): Until now, the use of minimal residual disease (MRD) testing in patients with acute lymphoblastic leukaemia (ALL) outside of a clinical trial program has not been standardised. Testing has been dependent on factors such as patient age and transplant considerations, largely because testing has not been funded through the Medicare Benefits Schedule (MBS). Well, that’s all changed, and now all patients with ALL are eligible for a total of twelve MRD tests per disease episode.

So, how will this affect clinical decisions, what will it mean for the treatment landscape, and how do we decide at what intervals to do these tests? Listen to this two-part interview to learn more…

Host

Associate Professor Ashley Ng

Clinical Haematologist, The Royal Melbourne Hospital & Peter MacCallum Cancer Centre.

Guest Experts

  • Dr Shaun Fleming

    Dr Shaun Fleming

    Consultant Haematologist, Monash Health & Alfred Health, Melbourne

  • Dr Michael Osborn

    Dr Michael Osborn

    Royal Adelaide Hospital, Adelaide.


Epilepsy Miniseries (Part 3)

Addressing the treatment gaps with generalised tonic-clonic seizures
20-Minutes
Show more info
Play preview - to listen to full interviews
or Subscribe

Epilepsy Miniseries (Part 3): There is universal agreement that primary generalised tonic-clonic seizures (PGTCS) are the most severe form of epileptic seizure. The treatment of PGTCS has been the subject of relatively few robust clinical studies, leading to significant unmet clinical needs in this patient population. Not only are there few treatment options available, but a significant proportion of patients who are treated with currently available drugs have insufficient seizure control or unacceptable drug tolerability. In this interview we discuss the importance of optimising the early treatment of PGTCS, including treatments with demonstrated effectiveness in this group. 20-minute listen

Host

Professor Mark Cook

Consultant Neurologist, Director of Neurology and Chair of Medicine, St Vincent’s Hospital Melbourne.

Guest Experts

  • Associate Professor Lata Vadlamudi

    Associate Professor Lata Vadlamudi

    Neurologist, The Royal Brisbane and Women’s Hospital, Brisbane.


Gastroenterology Miniseries (Part 4)

The forgotten part of ulcerative colitis
26-Minutes
Show more info
Play preview - to listen to full interviews
or Subscribe

Gastroenterology Miniseries – Dr Falk (Part 4).

The treatment paradigm in ulcerative colitis (UC) is rapidly evolving beyond symptom control with the aim of achieving mucosal healing and steroid-free remission, associated with reduced rates of UC-related hospital admissions, avoiding the need for a colectomy, and improving quality of life.

It’s important that we make the most of the treatments we have, and not give up on a treatment if there’s a chance to make it work. 

In this interview we discuss the optimisation of 5-ASA medications in the management of patients with mild to moderate UC.

Host

Associate Professor Mayur Garg

Director of Gastroenterology and Research Executive Committee Officer, Northern Health, and Clinical Associate Professor, University of Melbourne.

Guest Experts

  • Professor Peter Irving

    Professor Peter Irving

    Gastroenterologist, Guy's and St Thomas' Hospital, London, UK.


 Endocrinology

New developments in diabetes
20-Minutes
Show more info
Play preview - to listen to full interviews
or Subscribe

Endocrinology: Prof. MacIssac and A/Prof. Rasalam were both lead authors in a recent review titled, ‘Challenging clinical perspectives in type 2 diabetes with tirzepatide, a first-in-class twincretin’ published in Diabetes Therapy. In this interview Prof. MacIssac and A/Prof. Rasalam discuss key highlights of this review, as well as how these developments may affect the treatment algorithm of type 2 diabetes in Australia.

Host

Professor Richard MacIsaac

Professor and Director of Endocrinology, Department of Endocrinology & Diabetes, St Vincent’s Health, Melbourne.

Guest Experts

  • Associate Professor Roy Rasalam.

    Associate Professor Roy Rasalam.

    Clinical Professor, University of Melbourne, VIC.


Haematology

A new triplet combination for the treatment of relapsed and refractory multiple myeloma
27-Minutes
Show more info
Play preview - to listen to full interviews
or Subscribe

For haematologists, myeloma remains one of the most challenging diseases we deal with, there is no ‘one-size-fits-all’ approach to the management of multiple myeloma, and this is especially true for relapsed or refractory disease. With the right choice of agents we can control the disease for many years , but how we sequence those agents and how we use them in combination really is something we’re still working out, and we’re often dealing with limitations from the Pharmaceutical Benefits Scheme. In this interview we talk through these challenges, to help navigate this journey in clinical practice.

Host

Professor Christopher Ward

Clinical Haematologist, Royal North Shore Hospital, Sydney.

Guest Experts

  • Prof. Hang Quach.

    Prof. Hang Quach.

    Director of Clinical Haematology & Clinical Haematology Research, St Vincent’s Hospital, Melbourne.

  • Dr Wojt Janowski.

    Dr Wojt Janowski.

    Haematologist, Hunter region, NSW.


Endocrinology

New developments in induction of labour
24-Minutes
Show more info
Play preview - to listen to full interviews
or Subscribe

Induction of labour is a daily occurrence in obstetric units around Australia, and rates of induction have been rising nationally for the past decade. The Australian Institute of Health and Welfare data shows that in 2020, 46% of first-time mums with an uncomplicated pregnancy had their labour induced. In this interview we explore new developments in the induction of labour.

 

Host

Professor Rod Baber

Clinical Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health, The University of Sydney.

Guest Experts

  • Dr Scott White.

    Dr Scott White.

    Obstetrician & Gynaecologist, Perth, Western Australia.


Gastroenterology Miniseries (Part 3)

Could multidisciplinary team meetings be the future?
22-Minutes
Show more info
Play preview - to listen to full interviews
or Subscribe

Gastroenterology Miniseries (Part 3).

Multidisciplinary team meetings have proven efficacy in cancer management as well as being widely implemented in the management of chronic diseases like inflammatory bowel disease, however not all treating clinicians (particularly those in rural/regional areas, or even many of those in private practices) have access to these high quality and integrated meetings.

Given the potential for an MDT-based approach to potentially improve patient quality of care, patient satisfaction and patient outcomes, it only makes sense that such a service can be offered to the wider gastroenterology community.

In this interview we talk to Jake Begun, who along with his team at Queensland IBD have implemented the first dedicated state-wide virtual MDT in Australia.

Host

Associate Professor Mayur Garg

Director of Gastroenterology and Research Executive Committee Officer, Northern Health, and Clinical Associate Professor, University of Melbourne.

Guest Experts

  • Associate Professor Jake Begun

    Associate Professor Jake Begun

    Director of Gastroenterology, Mater Hospital Brisbane, & Associate Professor, University of Queensland School of Medicine, & Co-Director Queensland IBD.


Search Interviews

Log in

You must login or join to access this content

×

Tap the share icon ios share icon and select 'Add to Home Screen' to add the site to your home screen for quick access!